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Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting millions of people in the world. Cognitive 
impairments such as progressive memory loss are devastating manifestations from this disease. Current pharmacological 
treatment has limited efficacy and only provides symptomatic relief without long-term cure. As a result, cell-replacement 
therapy using stem cells is an emerging potential treatment to AD. In the last decade, there have been animal trials using stem 
cells to treat and modulate cognitive impairment in AD models via three different mechanisms—replacing the damaged or 
dead cholinergic neurons; protecting neurons by reducing toxic amyloid protein aggregates or insoluble tau neurofibrillary 
tangles and promoting neurogenesis in hippocampus by neurotrophic secretions from stem cells. All of the trials showed 
promising results and improved our understandings about the mechanism of dementia in AD. With the continued improve-
ment in safety profile of stem cell therapy and the creation of a better animal AD model in which to test them, it is feasible that 
stem cells could be trialled in humans for AD treatment in the next 5–10 years.
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Introduction
Currently, Alzheimer’s disease (AD) is the commonest cause 
of dementia (Dantuma, Merchant and Sugaya, 2010) affect-
ing over 24 million people worldwide (Ferri et al., 2005). For 
adults over 60s, dementia is even the fourth greatest global 
disease burden according to a World Health Organisation 
(2003) report published in 2003. Because of the gradual age-
ing population, it has been predicted that around 81 million 
people will have dementia by 2040 (Ferri et al., 2005). 
Patients with AD suffer from memory dysfunction and inabil-
ity to learn, and some can develop psychotic symptoms such 
as hallucination and delusions (Blennow, de Leon and 
Zetterberg, 2006). The disease was first described by a 
German neuropathologist, Alos Alzheimer (Goedert and 
Spillantini, 2006). He identified the presence of amyloid-beta 
(Aβ) plaques and neurofibrillary tangles in the brain as two 
classical hallmarks of AD. Aβ plaques are misfolded protein 
accumulated extracellularly, which are neurotoxic, and could 
lead to neuronal loss. Neurofibrillary tangles are insoluble 
aggregates of hyperphosphorylated tau protein, an intracel-
lular cytoskeletal molecule (Mattson, 2004; Blennow, de 
Leon and Zetterberg, 2006). Although the causative mecha-
nism between Aβ plaques and tau neurofibrillary tangles is 
still unclear, it is thought the combination of both leads to 
neuronal and synaptic loss in various cortical regions in the 
brain, resulting in cognitive decline and memory loss 
(Dantuma, Merchant and Sugaya, 2010).
Cholinergic neurons in the brain are especially vulnerable to 
damage by AD (Geula et al., 2008). They produce the neu-
rotransmitter acetylcholine, which is important in the control 
of sleep–wake cycle, consciousness, learning and memory pro-
cessing (Schliebs and Arendt, 2011). These neurons  originate 
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from the basal forebrain, in a region known as the nucleus 
basalis of Meynert (nbM) and project to various cortical 
regions in the brain (Selden et al., 1998). In AD, a hypothesis 
called the ‘cholinergic hypothesis’ states that the level of cog-
nitive decline in the AD patient directly correlates with the 
decrease of cholinergic neurons in the nbM (Bartus et al., 
1982). To rescue the effects of the damaged cholinergic neu-
rons, there are two types of drugs currently used in AD 
patients—acetylcholinesterase inhibitors such as donepezil 
and galantamine, which prevent the degradation of acetyl-
choline at the synapse, and memantine, an N-methyl-d-
aspartate receptor antagonist, which protects cholinergic 
neuronal death from excitotoxicity (Roberson and Mucke, 
2006). However, these drugs have variable efficacy and only 
provide symptomatic reliefs without long-term cure 
(Borlongan, 2012). Therefore, a novel treatment is needed to 
be found to cure AD. Recently, there have been advance-
ments using stem cell therapy to successfully treat neurologi-
cal conditions such as stroke, Parkinson’s disease, spinal cord 
injury and amyotrophic lateral sclerosis (Lu et al., 2003; 
Goldman, 2005; Park et al., 2006; Ebert et al., 2008; Kim 
and de Vellis, 2009). As a result, the therapeutic potential of 
stem cell in restoring cognition has been investigated exten-
sively. Over the past few years, there has been growing evi-
dence from different animal trials (Table 1). Here I will 
review recent studies that have used stem cell therapy in ani-
mal models of AD or cognitive decline and consider the effec-
tiveness of this approach for restoring cognitive function.
Which stem cell to use?
Stem cells are characterized by their unique properties of self-
renewal and their ability to differentiate into different cell 
lineages (Dantuma, Merchant and Sugaya, 2010). There are 
many types of stem cells in the body which can broadly be 
divided into embryonic and adult (somatic) stem cells. 
Embryonic stem (ES) cells are pluripotent, which means they 
have the ability to differentiate into different germ layers giv-
ing rise to different types of progenitor cells. ES cells develop 
into multipotent adult stem cells such as neural stem cells 
(NSCs) and mesenchymal stem cells (MSCs), which can only 
differentiate into a specific cell type (Mimeault, Hauke and 
Batra, 2007).
NSCs reside within the brain and can be differentiated 
into neurons, astrocytes and oligodendrocytes (Taupin, 
2006). Originally, it was thought that neurogenesis only 
takes place in the foetus. However, recent studies showed 
that this process also happens in adult’s brain and NSCs were 
found in the subgranular zone (SGZ) and subventricular zone 
(SVZ) (Taupin, 2006; Mu and Gage, 2011). The SGZ is 
located within the hippocampus, part of the brain which is 
important in learning and memory formation (Squire, 1992). 
Therefore, it seems like NSCs are obvious choice for the 
replacement of damaged neurons. Qu et al. (2001) were one 
of the earliest groups to prove this by implanting human 
NSCs into the brains of aged and mature rats. They showed 
that the NSCs survived and were differentiated into neurons 
and astrocytes in the rats’ brains. Also, a significant improve-
ment in cognitive function for the aged rats with memory 
impairment was observed after the transplantation compared 
with the control, correlating with the differentiated neurons 
in the hippocampus. However, the neuronal marker used in 
this study, βIII tubulin, only labels immature neurons. 
Therefore, further physiological investigations were required 
to prove that neurons derived from the NSCs were fully func-
tional. The group also discovered an increase in the astrocyte 
density within a part of the hippocampus (outside of the 
transplantation site) where astrocytes are not normally 
found. Because astrocytes are important structural and meta-
bolic support cells within the brain (Doetsch, 2003), this sug-
gests NSCs do not only replace or strengthen the neural 
circuit but they might also create an environment for the 
growth and support for neuronal fibres (Isacson et al., 1995).
Pluripotent ES cells were once thought to be an ideal can-
didate for stem cell therapy as they have the most potential to 
divide and differentiate. However, safety is the greatest con-
cern for the use of ES cells. One group compared the use of 
ES cells and ES cell-derived NSCs by transplanting them into 
the cortex of a mouse model of AD (Wang et al., 2006). They 
found the cognitive deficits actually worsened with ES cell 
transplantation because the stem cells induced a teratoma 
(a tumour with mixed cell types). Moreover, the use of 
embryonic cells generates much ethical debate (Juengst and 
Fossel, 2000), hence NSCs are more commonly used.
Unfortunately, NSCs are very difficult to obtain from 
adult’s brain and so current studies mainly use foetal NSCs, 
which could also generate ethical problems. Very recently, it 
was found that MSCs derived from bone marrow, umbilical 
cord blood and adipose tissue could be transdifferentiated 
into neuronal cells (Brazelton et al., 2000; Mezey et al., 2000; 
Kim et al., 2012). Studies using MSC transplantation on AD 
animal models have shown promising results on their 
improvement in cognitive function (Babaei, Soltani Tehrani 
and Alizadeh, 2012; Lee et al., 2012). Babaei, Soltani Tehrani 
and Alizadeh (2012) induced an nbM lesion in the rats with 
an excitotoxin to model cognitive decline in AD. The rats 
then received either MSC or a sham infusion into the hippo-
campus. They showed that learning and memory significantly 
improved in the group which received MSCs compared with 
the sham infusion. As the MSCs were derived from rat tibia, 
this shows we might be able to harvest stem cells from the 
adult bone marrow to develop a treatment for AD. However, 
no neuropathological investigation was done in this study to 
correlate the outcome with the differentiation of MSCs into 
functional neurons in the hippocampus. Also, interspecies 
variation could mean the results shown were only applicable 
when using murine MSCs. Therefore, it would be useful to 
transplant MSCs from human bone marrow and include neu-
ropathological investigations to look at survival and differen-
tiation of MSCs in future studies. In another study, MSCs 
derived from human umbilical cord blood were transplanted 
into the hippocampus of transgenic mice model of AD 
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Table 1.  Summary of recent stem cell therapy studies on animal models of AD and cognitive decline
Study
Types of stem 
cell 
transplanted
Models/methods of 
cognitive decline induction Transplant site
Outcome in cognition and/or pathology in the 
brain post-transplantation
Babaei et al. 
(2012)
Murine 
BM-MSC
1.   Aged rats (30 months)
2.   Ibotenic acid-induced 
NBM lesion rats
Hippocampus  
(CA-1 region)
1.   Aged rats—learn more rapidly
2.   Ibo-induced memory impairment group—sig-
nificant reduction in latency to find platform in 
Morris Water Maze
Blurton-
Jones et al. 
(2009)
mNSC Triple transgenic AD model mice (3xTg-AD) Hippocampus
 NSC transplant rescues learning and memory 
deficits
 No change in Aβ, tau pathology but increased 
synaptic density in mice’s hippocampus
Esmaeilzade 
et al. (2012) EPI-NCSC
Rat hippocampal Aβ 
injection Hippocampus
Significant improvement in cognitive tasks (Y-maze 
and passive avoidance tests), increased neuron 
number and differentiation into other cell type
Kern et al. 
(2011) mNSC DS model mice (Ts65Dn) Hippocampus
Decreased tau-positive clusters in trisomic (28.6%) 
and disomic (58.6%) mice
Kim et al. 
(2012) Human ASC
Transgenic AD-model mice 
(Tg2576)
1.   Intravenous 
2.   Hippocampus 
(bilateral 
dentate gyrus)
 Both intravenous and intracerebral ASC transplan-
tation rescued memory impairment and improved 
spatial learning;
 Reduced amyloid plaque formation, upregulated 
interleukin-10 and neurotrophic factors in the 
brain of Tg2576 mice
Lee et al. 
(2009)
Murine 
BM-MSC
Acute Aβ-induced model 
mice
Hippocampus 
(dentate gyrus)
BM-MSCs promoted microglial activation
 Reduced Aβ deposits of acutely induced AD mice
Lee et al. 
(2012)
Human 
UCB-MSC
APP and presenilin (PS1) 
double-transgenic mice Hippocampus
Improved spatial learning and memory in Morris 
Water Maze tests
 Reduced Aβ load and tau hyperphosphorylation, 
inhibited proinflammatory cytokine release from 
microglia
Park et al. 
(2010) hNSC Aged rats (22 months)
Intracerebro-
ventricular SGZ increased in cell number
Park et al. 
(2012) hNSC
AF64A cholinotoxin injection 
in rats
Right lateral 
ventricle
Rats receiving NSCs overexpressing ChAT showed 
full recovery in learning and memory functions, 
whereas those receiving NSCs only remained 
memory impaired
Qu et al. 
(2001) hNSC
1.   Matured rats (6 months)
2.   Aged rats (24 months)— 
memory impaired and 
unimpaired
Right lateral 
ventricle
 Cognitive function significantly improved in 
matured and aged memory-impaired groups
 Morphologically functional hNSC-derived cells 
were found in the hippocampus and cortex
Wang et al. 
(2006)
Murine ES and 
ES-derived 
NSC
Ibotenic acid-induced NBM 
lesion mice
Frontal association 
cortex and barrel 
field of S1 cortex
NPC restored memory, ES significantly decrease 
working memory; ES induced massive teratoma 
formation
Xuan et al. 
(2009)
mNSC and 
NSC-derived 
glial cells
Rat Fimbria-Fornix 
transaction Basal forebrain
Improved memory and learning in Y-maze testing;
 Increased in the number of p75NGFR-positive 
neurons
Yamasaki 
et al. (2007) mNSC
Double transgenic neuronal 
injury model mice (CaM/
Tet-DTA)
Hippocampus Improved hippocampal-dependent memory and increased synaptic density and neuronal number
Aβ, amyloid-beta; AD, Alzheimer’s disease; APP, amyloid precursor protein; ASC, adipose-derived stem cell; BM-MSC, bone marrow mesenchy-
mal stem cell; ChAT, choline-acetyltransferase; EPI-NCSC, epidermal neural crest stem cell; ES, embryonic stem cell; NGFR, nerve growth factor 
receptor; NSC, human neural stem cell; hNSC, human neural stem cell; mNSC, murine neural stem cell; UCB-MSC, umbilical cord blood 
mesenchymal stem cell.
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(Lee et al., 2012). In this case, not only did the transplanted 
group show significant improvement in cognitive function, 
Aβ deposition in the brain and hyperphosphorylated tau 
were also decreased. The change in the AD pathology was 
associated with the modulation in neuroinflammation in 
which an upregulation of anti-inflammatory cytokines was 
found. These results were promising that it prompted for fur-
ther research on humans to correlate neuroinflammation 
with AD, and the use of MSCs could potentially be developed 
as a novel immunomodulatory treatment for AD.
Replacing cholinergic neurons with 
stem cells
Cholinergic neurons that originate from the nbM are essen-
tial for cognitive functioning. Therefore, an induced lesion 
on the cholinergic system is commonly used as AD models to 
determine whether stem cell therapy could replace choliner-
gic neurons and restore cognitive function. Xuan et al. 
(2009) demonstrated that engrafted NSCs do increase the 
number of cholinergic neurons and enhance memory and 
learning in AD-model rats. They simulated cognitive impair-
ment by performing a unilateral fimbria–fornix transaction 
in the rat’s brain to disrupt the cholinergic neuronal circuit 
between the brain septum and the hippocampus. Significant 
improvement in learning and memory was observed after 
transplantation of the NSCs. Also, immunohistochemistry 
studies showed that a significantly higher number of cholin-
ergic neurons were found on the transplanted group com-
pared with the lesioned group. However, the study did not 
show whether the stem cells actually differentiate into 
 cholinergic neurons or whether the NSCs were secreting 
neurotrophic factors to stimulate neurogenesis. Interestingly, 
NSCs seem to preferably differentiate into glial cells, which 
are structural neuronal cells. But there were no improvement 
in cognitive function nor an increase in cholinergic neurons 
when isolated glial cells were transplanted into the rats’ 
brains. This suggests glial cells do not have a direct role in 
cognitive functioning, but their presence might be important 
for NSCs to stimulate neurogenesis to replace or protect 
cholinergic neurons.
Since the replacement of cholinergic neurons is important 
to restore memory and learning, would it not be more effi-
cient if we transplant cells that could secrete more acetylcho-
line? Park et al. (2012) answered this question by 
transplanting NSCs, which are genetically programmed to 
over-express choline acetyltransferase (ChAT), an enzyme 
used for the synthesis of acetylcholine, into an AD-model rat. 
They found that the modified NSCs synthesized more ChAT 
than the normal NSCs and could significantly improve cogni-
tive function. However, strangely, they showed normal NSCs 
had actually no effects on restoring memory on the rats. One 
major caveat about this study is the model they used to simu-
late cognitive decline in AD. A cholinotoxin, AF64A, was 
used to reduce the release of acetylcholine in the brain by 
altering ChAT mRNA expression in cholinergic neurons. 
This means the transplanted NSCs might actually be affected 
by the cholinotoxin. Hence, only the genetically programmed 
NSCs could overcome the effect by over-synthesizing 
ChAT enzyme. Nevertheless, this study suggests the simple 
 replacement of cholinergic neurons is not sufficient in restor-
ing cognitive function in AD.
Clearing up the misfolded protein 
aggregates using stem cell therapy
As previously mentioned, Aβ plaques and tau neurofibrillary 
tangles are toxic aggregates, which might damage neurons in 
the brain. Since implanted stem cells typically differentiate 
and migrate to areas with neuronal loss (Imitola et al., 2004), 
would stem cells have a role in the clearance of the misfolded 
protein? To tackle this question, Kern et al. (2011) investi-
gated the effects of neural stem cell transplantation in the 
mice model of Down syndrome (DS). DS and AD are similar 
in a way that many patients with DS have progressive mem-
ory decline and possess typical plaques and tangles on neuro-
pathological studies. In this particular mouse model, there is 
neuronal cell loss and an increase in tau-clustered granules 
especially in the hippocampal region. The group implanted 
murine NSCs or saline as a control into the hippocampus of 
DS mice. One month after transplantation, they found the 
number of tau clusters were significantly lower in the NSC-
transplanted group, suggesting NSCs might have a role in the 
reduction of tau aggregates. Interestingly, the clearance of tau 
neurofibrillary tangles was also found on the opposite side of 
the transplantation without the migration of NSCs. This sug-
gests NSCs do not physically reduce tau tangles, but soluble 
growth factors secreted by NSCs might regulate tau phos-
phorylation throughout the brain. However, it would be 
wrong to assume that the same will happen in humans as the 
appearance of tau neurofibrillary tangles is different between 
humans and mouse (Gotz, 2001), which is one main flaw of 
this study.
Another group has looked at bone marrow-derived MSC’s 
role in the reduction of brain Aβ plaques. Lee, Jin and Bae 
(2009) injected soluble aggregated Aβ into the mouse hippo-
campus to induce an acute AD model. They transplanted 
murine MSCs from the bone marrow into the hippocampus 
and found Aβ deposition disappeared after 7 days of trans-
plantation. Activated microglia, the macrophages in the 
brain, was shown to be increased in the transplanted group 
compared with the control. The study therefore concluded 
that grafted bone marrow–MSCs might induce microglial 
activation and recruitment, leading to phagocytosis to clear 
up Aβ plaques in the brain (Lee, Jin and Bae, 2009).
Altering neurogenesis to restore 
memory function
From the two studies above, stem cells were shown to reduce 
or protect neurons from toxic aggregation of misfolded pro-
tein. However, both studies failed to investigate the effects of 
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plaques or neurofibrillary tangles clearance on cognitive 
function. A year later, Blurton-Jones et al. (2009) published a 
study showing that cognitive decline in a transgenic mice 
model of AD could actually be rescued by NSC therapy 
 without altering the levels of Aβ or tau protein. Interestingly, 
a previous imaging study showed similar findings which sug-
gested that plaques and tangles could accumulate for many 
years before cognitive function starts declining (Kemppainen 
et al., 2007). Blurton-Jones et al. (2009) also demonstrated 
that cognitive improvement correlated positively with neuro-
genesis as they found an increase in brain-derived neuro-
trophic factor (BDNF), which has role in synaptogenesis and 
neuronal networking (Aguado et al., 2003). From this we 
could hypothesize that the cause of dementia in AD is due to 
the reduction in neurogenesis caused by the exhaustion of 
NSCs from long-term toxic damage by Aβ plaques or tau 
neurofibrillary tangles. Post-mortem immunohistochemical 
studies in AD cases to investigate co-localization between 
NSCs and aggregated proteins could be helpful to identify the 
interaction between Aβ, tau and NSCs.
Increasing evidence has shown that cognitive function is 
linked to the alteration of neurogenesis in the adult hippo-
campus. Surprisingly, it emerges that depression could also be 
caused by a decrease in hippocampal neurogenesis (Duman, 
2004) like AD and antidepressive medication could promote 
neurogenesis in the hippocampus of rodents. Therefore, 
Chang et al. (2012) carried out an in vitro study which dem-
onstrated that fluoxetine, an antidepressant, could stimulate 
NSCs proliferation and protect stem cells from Aβ cytotoxic-
ity (Chang et al., 2012). This provides a potential use of 
fluoxetine in future studies of stem cell transplantation in 
restoring cognitive function.
With regard to stem cell therapy, it is now believed that 
the increase in neurogenesis rather than purely the replace-
ment of cholinergic neurons leads to an improvement in cog-
nition. As mentioned earlier, stem cells could provide a 
neurotrophic environment by the production of BDNF 
(Blurton-Jones et al., 2009). They could also differentiate 
into glial cells which secrete different neurotrophic factors 
(Xuan et al., 2009) to promote neurogenesis. Therefore, in 
future studies, we might see the rise in the use of genetically 
modified stem cells to deliver neurotrophic factors, which 
stimulate neurogenesis for the treatment of cognitive decline 
in AD models.
The future of stem cell therapy for 
Alzheimer’s disease
AD is a complex disease which affects different neural cell 
types and has a diffuse pathology (Chen and Blurton-Jones, 
2012). Therefore, there are limitations on the animal studies 
as only certain aspects of AD could be modelled. Transgenic 
models of AD are the most current animal model used, which 
display the nature of cognitive decline with typical AD 
pathology in familial AD. However, only <5% of AD is 
familial (Young and Goldstein, 2012) and there are yet no 
animal models which can simulate the sporadic and progres-
sive nature of AD. Moreover, co-morbidity factors such as 
age and cardiovascular events could not be accounted for in 
current AD models (Borlongan, 2012).
Recent animal studies have shown that learning and mem-
ory deficit could be improved by stem cell therapy. But, in all 
studies, the assessments of cognitive improvement were per-
formed only shortly after stem cell transplantation without 
much follow-up. As AD is a progressive disease, longer term 
studies are needed to look at lasting effects as well as safety 
profile of the treatments (Borlongan, 2012).
With the recent advancements of reprogramming technol-
ogy, there is a great potential in the use of inducible pluripo-
tent stem cell (iPSC) in the treatment of AD. Somatic cells 
from patients could be reprogrammed to generate iPSCs, 
which could then be directed into the differentiation of neural 
precursor cells for transplantation (Jung et al., 2012). This 
means tissue rejections due to immunological incompatibility 
will no longer be an issue and there will be fewer ethical prob-
lems. Also, it can improve the modelling of neurodegenerative 
diseases like AD because iPSCs could differentiate into neu-
rons, which contain the unique genetic phenotype of the 
patient (Young and Goldstein, 2012). This creates a model 
which offers the closest approximation to the sporadic form 
of the disease and hopefully could be translated into human 
studies to find a cure for AD.
Conclusion
Stem cell therapy in recent years has shown promising results 
in rescuing cognitive decline on animal models of AD. These 
help us understand more about cognitive functioning and the 
mechanisms which leads to memory loss in AD. More evi-
dence has also shown that the decline of neurogenesis, rather 
than simply the accumulation of protein aggregates, contrib-
utes to dementia in the AD patients. Therefore, future studies 
should focus on using stem cells to deliver neurotrophic fac-
tors for the alteration of neurogenesis in AD models. 
However, most of the current research is hype as there were 
safety (e.g. ES induced tumourigenesis) and ethical issues 
involved in the use of foetal stem cells. Also, there is not a 
single animal model which could simulate the full aspect of 
AD. Nevertheless, there is still hope—the use of MSCs is free 
from ethical problems and could potentially be a type of 
immunomodulatory treatment for AD. Also, with the 
advancement in the use of iPSC, hopefully we could model 
the disease better and eventually translate stem cell research 
into human studies with the aim to finally solve the enigma of 
restoring the memory.
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